AA-MEDROXY 5 MG
MEDROXYPROGESTERONE ACETATE : 5 MG · DIN 02244727 · AA PHARMA INC
Health Canada status: MARKETED
What is AA-MEDROXY?
AA-MEDROXY 5 MG contains MEDROXYPROGESTERONE ACETATE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02244727, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AA-MEDROXY used for?
Hormonal replacement therapy (to oppose estrogen); functional menstrual disorders; adjunctive/palliative treatment of recurrent/metastatic endometrial carcinoma or breast cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is AA-MEDROXY called?
The same molecule, MEDROXYPROGESTERONE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Provera | Latin | Australia |
| Ralovera | Latin | Australia |
| Depo-Provera | Latin | Australia |
| FARLUTAL | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02244727 |
|---|---|
| Brand name | AA-MEDROXY |
| Generic / active ingredient | MEDROXYPROGESTERONE ACETATE : 5 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03DA02 MEDROXYPROGESTERONE |
| AHFS class | 68:32.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Dec-2024 |
| Original market date | 2002-04-22 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02244727 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2244727 |
| Brand name | AA-MEDROXY |
| Active ingredient / INN | MEDROXYPROGESTERONE ACETATE : 5 MG |
| ATC code | G03DA02 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03 |
| AHFS class | 68:32.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | AA PHARMA INC |
How is it administered?
Oral. HRT: 5-10 mg daily for 12-14 days. Secondary amenorrhea: 5-10 mg daily for 12-14 days. Endometrial cancer: 200-400 mg daily. Breast cancer: 400 mg daily in divided doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in the provided text (standard storage section 11 was not included in the snippet).
How is it supplied?
Bottles of 100 and 500 tablets.
Which pack is which?
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Bottles of 100 and 500 tablets. |
| Storage | Not explicitly specified in the provided text (standard storage section 11 was not included in the snippet). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Liver dysfunction; known/suspected malignancy (unless treating breast/endometrial cancer); undiagnosed genital bleeding; pregnancy; history of thromboembolic disease; vision loss due to vascular disease.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Should be prescribed at lowest effective dose for shortest duration. May cause Cushingoid symptoms at high doses.
What can be used instead?
Other Canadian products sharing ATC code G03DA02 MEDROXYPROGESTERONE. 7 of 38 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-MEDROXY | 10 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02277298 |
| AA-MEDROXY | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02267640 |
| AA-MEDROXY | 2.5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02244726 |
| TEVA-MEDROXYPROGESTERONE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02221306 |
| TEVA-MEDROXYPROGESTERONE | 2.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02221284 |
| TEVA-MEDROXYPROGESTERONE | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02221292 |
| DOM-MEDROXYPROGESTERONE | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247583 |
| DOM-MEDROXYPROGESTERONE | 2.5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247581 |
| DOM-MEDROXYPROGESTERONE | 5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247582 |
| GEN-MEDROXY TABLET 10MG | 10 MG | TABLET | GENPHARM ULC | CANCELLED POST MARKET | DIN 02229840 |
Who else supplies MEDROXYPROGESTERONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MEDROXYPROGESTERONE appears in 62 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does MEDROXYPROGESTERONE cost around the world?
MEDROXYPROGESTERONE is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 31 | USD███.██ |
| Australia | ex-manufacturer | 3 | 19 | AUD███.██ |
| South Africa | single exit price | 7 | 8 | ZAR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
59 pack listings across 15 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every MEDROXYPROGESTERONE pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.